News

No news is bad news for Tocagen

Brain cancers are among the most difficult to treat, as Tocagen's struggles follow late-stage study failures earlier this month from AbbVie and Bristol-Myers Squibb. The...

Array gets a win in colorectal cancer

Array's combination of Braftovi (encorafenib) and Mektovi (binimetinib) already appears well received in the small clinical setting of advanced melanoma with BRAF V600E or...

Amicus widens UPenn gene therapy collaboration

Biopharma companies wanting to treat rare diseases are increasingly pressed to be invested in gene therapy. Novartis and Roche have recognized this with their...

Gilead firms up path to market for key arthritis drug

A filing this year for filgotinib could set up a potential market launch in 2020, which would be one to two years earlier than...

Zolgensma set a new drug pricing bar. Insurers show some signs of pushback

Zolgensma (onasemnogene abeparvovec) wasn't the first gene therapy approved in the U.S. That milestone belongs to Spark Therapeutics' Luxturna (voretigene neparvovec), a treatment for...

Former FDA head Gottlieb joins Pfizer board

While past FDA chiefs have joined drugmaker boards following their tenure, Gottlieb's move to Pfizer is both rapid and more high-profile than that of...

Bayer backs cell therapy startup with $215M in funding

First-generation cell therapies, such as those developed by Novartis and Gilead, rely on immune cells collected from each individual patient. A painstaking manufacturing process...

Once ‘bodies for hire,’ CROs are finding a new role as data specialists

Drugmakers want better designed, less expensive clinical trials. The demand is so great that contract research providers, often called CROs, are building out their...

Amgen bone drug application knocked back in Europe

Expectations for Evenity (romosozumab) are modest, and the rejection by the EMA is a "minor setback" for Amgen, according to RBC Capital Markets analyst...

AbbVie deal for Allergan not about the taxes, thanks to 2017 law

AbbVie CEO Rick Gonzalez finally achieved the overseas acquisition that he sought five years ago. But his deal for Allergan comes too late to...

Latest articles

CMS chief declines to provide details on Trump healthcare...

The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation...

Roche cancer drug the 3rd approved for pan-tumor use

Aimed at the molecular catalysts of tumor growth, targeted therapies are treatment mainstays across a wide range of cancer types. 

Novo faces shareholder suit over insulin sales disclosures

Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments...

Celgene wins approval for drug key to Bristol buyout

Approval of Inrebic, which was previously known as fedratinib, is the first domino to fall in Bristol-Myers bet on Celgene's product pipeline. 

Subscribe to our newsletter